UNSPSC 51433002: Rilmenidine

This classification denotes an antihypertensive agent with the molecular formula C10H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P67IM25ID8, chemically known as 2-oxazolamine, n-(dicyclopropylmethyl)-4,5-dihydro- but generally known as rilmenidine, which bears US NIH Compound Identifier 68712. European Medicines Agency schedules Rilmenidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10316MIG. The term RILMENIDINE is an International Non-Proprietary Name.

UNSPSC 51433002 Rilmenidine (Commodity) describes a specific antihypertensive pharmaceutical actively procured by state and local health agencies, though recent opportunities show rilmenidine explicitly named in RFPs and RFQs only when bundled into broader medication contracts or pharmaceutical supply frameworks. State and local governments buy rilmenidine through emergency medical services systems, health and human services agencies, and state cooperative purchasing programs that source generic and brand-name pharmaceuticals for distribution across multiple jurisdictions. The City of Tampa's Purchasing Department, Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have all posted pharmaceutical supply solicitations in 2026 that would logically encompass rilmenidine as a line item within larger medication portfolios, though rilmenidine does not appear by name in publicly available opportunity summaries. Issuing bodies include city-level emergency services departments (Tampa Fire Rescue), state health agencies (Texas HHS), and multistate cooperative purchasing consortia administering contracts across participating states and local governments.

Activity concentrates in Texas, Minnesota, and Florida based on recent 2026 postings. The City of Tampa's Advanced Life Support Medications IFB (solicitation 26P00188, due April 8, 2026, estimated value $40,000) procures four specific emergency cardiac medications for fire rescue operations with nine-month minimum shelf life and ten-day delivery. The Minnesota Multistate Cooperative Purchasing Alliance RFP (S1070000015802, due March 26, 2026) establishes statewide contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026 for two-year terms. Texas HHS issued an RFI (HHS0017013, April 2026) exploring direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager channels, signaling intent to develop formal pharmaceutical procurement mechanisms. Cooperative purchasing vehicles dominate the state-level landscape, while individual municipal and county health agencies issue discrete RFQs and IFBs for near-term medication supply.